Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 26, 2011

Pfizer Selects Parexel and Icon to Implement and Manage Clinical Trials

  • Pfizer has selected Boston-based Parexel, and Dublin, Ireland-based Icon, as its two preferred CROs for the provision of clinical development and trials services. The partnership agreements will be phased in over an 18–24-month period and will initially run for five years. Pfizer says the deals are in line with its remodeled R&D strategy, which involves partnering with third parties for services such as the implementation of clinical development programs. This will enable Pfizer to focus internally on its core strength in clinical trials design.

    “This new strategic partnership model is part of a comprehensive program to sharpen our research focus at Pfizer and creates a more flexible cost-base,” comments John Hubbard, svp for worldwide development at Pfizer.

    Under terms of the agreements, Pfizer will retain scientific ownership of clinical development processes and retain an overseeing role. Its new partners will provide their respective expertise in carrying out and managing global clinical trials, evaluating trail sites and countries, and optimizing and implementing data management, as well as reporting setup, fronting scientific and medical communications, and maintaining quality assurance.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »